BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsCompany update

CHICAGO --(BUSINESS WIRE)--Apr. 3, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2026, the

Open original release

Related news

XERSXeris Pharmaceuticals2026-04-23 11:30 EST

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

IKTInhibikase Therapeutics2026-07-02 20:01 EST

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XERSXeris Pharmaceuticals2026-05-07 11:00 EST

Xeris Biopharma Reports First Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-05-05 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-05-01 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-06-05 12:01 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-03-16 20:05 EST

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Xeris Pharmaceuticals

Xeris Pharmaceuticals is a specialty pharmaceutical company focused on injectable and liquid formulations for endocrine, neurologic, and gastrointestinal conditions. Its commercial base is tied to product delivery and convenience.

Recent company news

XERSXeris Pharmaceuticals2026-05-07 11:00 EST

Xeris Biopharma Reports First Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-04-23 11:30 EST

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

XERSXeris Pharmaceuticals2026-04-03 20:15 EST

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

XERSXeris Pharmaceuticals2026-03-02 12:00 EST

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

XERSXeris Pharmaceuticals2026-02-26 22:55 EST

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Stock data

Close
8.21 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States